http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen). http://medicalxpress.com/news/2013-04-clinical-trial-class-cancer-drugs.html Cancer Tue, 09 Apr 2013 15:00:01 EST news284730889 (Medical Xpress)—Important new research from UMass Medical School demonstrates how exosomes shuttle proteins from neurons to muscle cells where they take part in critical signaling mechanisms, an exciting discovery that means these tiny vehicles could one day be loaded with therapeutic agents, such as RNA interference (RNAi), and directly target disease-carrying cells. The study, published this month in the journal Neuron, is the first evidence that exosomes can transfer membrane proteins that play an important role in cell-to-cell signaling in the nervous system. http://medicalxpress.com/news/2013-03-intercellular-potential-rnai-gene-based-therapeutics.html Neuroscience Wed, 27 Mar 2013 10:10:01 EST news283596137 Researchers employed an extensive analysis of genomic information to identify a new, high-risk cohort of ovarian cancer patients, characterize their tumors, find a potential treatment and test it in mouse models of the disease. http://medicalxpress.com/news/2013-02-deep-genomic-analysis-micro-rna.html Cancer Mon, 11 Feb 2013 15:37:36 EST news279819376 A study led by Dr Josep Tabernero, the Director of Clinical Research at the Vall d'Hebron Institute of Oncology (VHIO) and Head of the Medical Oncology Department at the Vall d'Hebron University Hospital, shows for the first time that ribonucleic acid interference (RNAi) is effective in the treatment of cancer patients. Harnessing these molecules to silence genes involved in the development and growth of cancer cells is an important step forward in developing a new and more targeted type of cancer therapy. http://medicalxpress.com/news/2013-02-first-in-man-therapeutic-effect-rnai-gene.html Cancer Mon, 11 Feb 2013 08:46:49 EST news279794788 (HealthDay)—Noncanonical Hedgehog (Hh) signaling is activated in tamoxifen-resistant tumors, and the phosphoinositide 3-kinase inhibitor/protein kinase B (PI3K/AKT) pathway plays a key role protecting Hh signaling molecules, according to a study published in the Oct. 1 issue of Cancer Research. http://medicalxpress.com/news/2012-11-hedgehog-pathway-key-tamoxifen-resistant-breast.html Cancer Tue, 06 Nov 2012 16:40:01 EST news271441074 Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is usually treated with surgery and chemotherapy. However, a small group of patients can also be helped by treatment with tyrosine kinase inhibitors (TKI). New research published in BioMed Central's open access journal BMC Medicine, shows that blocking production of epidermal growth factor receptor (EGFR) using RNAi, alongside TKI (or antibody therapy), could enhance the effect of TKI on NSCLC cell death, and slow cell growth. http://medicalxpress.com/news/2012-03-whammy-rnai-lung-cancer-therapy.html Cancer Tue, 20 Mar 2012 20:00:01 EST news251481908 Oncolytic virology uses live viruses to sense the genetic difference between a tumor and normal cell. Once the virus finds a tumor cell, it replicates inside that cell, kills it and then spreads to adjacent tumor cells to seed a therapeutic "chain reaction". As reported in today's issue of Cancer Cell, Dr. David Stojdl, a scientist from the Children's Hospital of Eastern Ontario Research Institute at the University of Ottawa has found a way to trick resistant cancer cells into committing suicide following oncolytic virus therapy. http://medicalxpress.com/news/2011-10-cheo-scientist-advances-biotherapeutics-published.html Cancer Tue, 18 Oct 2011 09:39:21 EST news238149551